Abstract:Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses to prevent tissue damage and autoimmunity, are often exploited by cancer cells to avoid destruction. The discovery of checkpoint proteins like PD-1/PD-L1 and CTLA-4 was pivotal in developing cancer immunotherapy. Immune checkpoint inhibitors (ICIs) have shown great success, with FDA-approved drugs like PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab, Tremelimumab), alongside LAG-3 inhibitor Relatlimab. Research continues on new checkpoints like TIM-3, VISTA, B7-H3, BTLA, and TIGIT. Biomarkers like PDL-1 expression, tumor mutation burden, interferon-γ presence, microbiome composition, and extracellular matrix characteristics play a crucial role in predicting responses to immunotherapy with checkpoint inhibitors. Despite their effectiveness, not all patients experience the same level of benefit, and organ-specific immune-related adverse events (irAEs) such as rash or itching, colitis, diarrhea, hyperthyroidism, and hypothyroidism may occur. Given the rapid advancements in this field and the variability in patient outcomes, there is an urgent need for a comprehensive review that consolidates the latest findings on immune checkpoint inhibitors, covering their clinical status, biomarkers, resistance mechanisms, strategies to overcome resistance, and associated adverse effects. This review aims to fill this gap by providing an analysis of the current clinical status of ICIs, emerging biomarkers, mechanisms of resistance, strategies to enhance therapeutic efficacy, and assessment of adverse effects. This review is crucial to furthering our understanding of ICIs and optimizing their application in cancer therapy.

Emerging immune checkpoint and its combination therapy in cancer treatment

Tumor Immune Checkpoints and Their Associated Inhibitors

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions

Immune checkpoint signaling and cancer immunotherapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

[Immune-checkpoints: the new anti-cancer immunotherapies]

Combination strategies to maximize the benefits of cancer immunotherapy

Next-generation combination approaches for immune checkpoint therapy

Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

Beyond immune checkpoint blockade: emerging immunological strategies